Taurolidine
- Generic Name
- Taurolidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H16N4O4S2
- CAS Number
- 19388-87-5
- Unique Ingredient Identifier
- 8OBZ1M4V3V
- Background
Taurolidine has been investigated for the prevention of Central Venous Catheter, Home Parenteral Nutrition, and Catheter-Related Infections.
- Indication
Not Available
- Associated Conditions
- Infection, Soft Tissues Infections, Tissue Adhesions, Perioperative infection
- Associated Therapies
- General irrigation therapy of the Abdominal Cavity
Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Prof. Dr. Hendrik Bonnemeier
- Target Recruit Count
- 1417
- Registration Number
- NCT05576194
- Locations
- 🇩🇪
Lakumed, Landshut, Bavaria, Germany
Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 20
- Registration Number
- NCT02515201
The AOT (Acridine Orange and Taurolidine) Trial
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-02-11
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00321165
- Locations
- 🇳🇱
Department of Gastroenterology and Hepatology clinical ward, Nijmegen, Netherlands
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00022360
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00021034
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath